JPRN-UMIN000001038已完成1 期
Multicenter phase I/II trial of adjuvant combination chemotherapy with gemcitabine and S-1 for pancreatic cancer - Phase I/II trial of adjuvant chemotherapy with gemcitabine and TS-1 for pancreatic cancer
Study Group for Adjuvant Chemotherapy of Pancreatic Cancer0 个研究点目标入组 55 人开始时间: 2008年4月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Watery diarrhea 2)Severe mental disorder 3)Active infection 4)Severe complications, such as ileus, heart failure and renal failure 5)Symptomatic pulmonary fibrosis or interstitial pneumonia 6)History of radiation therapy to the chest 7)Marked pleural or peritoneal effusion 8)Active concomitant malignancy 9)Treatment with phenytoin, potassium warfarin or flucytosine
研究者
相似试验
招募中
不适用
A Phase I/II Trial of combined adjuvant therapy with gemcitabine and cisplatin for resected biliary tract cancerResected biliary tract cancerJPRN-UMIN000004359Shinshu University School of Medicine, Surgery33
招募中
1 期
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma.MedDRA version: 20.0Level: PTClassification code: 10018337Term: Glioblastoma multiforme Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864glioblastomaCTIS2023-508278-26-01Z Brussel18
已完成
2 期
Phase II trial of neoadjuvant combination chemotherapy with gemcitabine and S-1 for locally advanced pancreatic cancerlocally advanced pancreatic cancerJPRN-UMIN000001450Faculty of Medicine, Kyoto University35
招募中
2 期
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.Hepatocellular CarcinomaNarrow MarginRadiotherapyNCT06205472Cancer Institute and Hospital, Chinese Academy of Medical Sciences100
招募中
2 期
Phase II trial exploring combined neoadjuvant therapy with Pembrolizumab/Lenvatinib and adjuvant Pembrolizumab in patients with surgically resectable Non-Small- Cell Lung Cancer (NSCLC)2024-514821-45-00Medizinische Universitaet Innsbruck33